22UA Stock Chart & Stats
€81.25
€0.65(0.81%)
At close: 4:00 PM EDT
€81.25
€0.65(0.81%)
Day’s Range― - ―
52-Week Range€68.30 - €105.70
Previous CloseN/A
Volume48.95K
Average Volume (3M)37.13K
Market Cap
€19.95B
Enterprise Value€6.84K
Total Cash (Recent Filing)€9.74B
Total Debt (Recent Filing)€315.97M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Nov 03, 2026EPS Estimate
0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.73
Shares Outstanding251,204,360
10 Day Avg. Volume26,648
30 Day Avg. Volume37,127
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.02
Price to Sales (P/S)7.10
P/FCF Ratio72.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€109.22Price Target Upside34.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-4.78
Revenue Forecast (FY)€1.58B
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetVery low leverage and substantial liquidity give BioNTech flexibility to fund costly clinical development, absorb commercial volatility and pursue strategic options without relying heavily on external financing.
Diversifying Oncology PipelineA broad, increasingly late-stage oncology portfolio can reduce dependence on COVID vaccines and create multiple potential product revenue streams, while combination programs and platform breadth may strengthen BioNTech's competitive position.
Encouraging Clinical ValidationMeaningful efficacy signals across distinct oncology mechanisms support continued investment and pivotal development. If confirmed, these results could underpin differentiated therapies and improve the probability of building a durable oncology franchise.
Bears Say
COVID Revenue DependenceThe sharp decline shows that the historical commercial engine remains exposed to an mRNA vaccine market with lower and less predictable demand. Oncology diversification may take time to offset the resulting revenue reset.
Persistent Operating LossesHigh R&D and scaling costs are no longer supported by the former vaccine revenue base, producing sizable losses. Sustained spending is strategically necessary, but prolonged negative margins could erode equity and reduce financial flexibility.
Pipeline Execution And Timing RiskDelayed data can defer regulatory and commercial milestones, while concentrated collaboration revenue increases dependence on timing and recognition. Together, these issues make the transition from vaccine-led sales to oncology revenue less predictable.
BioNTech SE News
22UA FAQ
What was BioNTech SE’s price range in the past 12 months?
BioNTech SE lowest stock price was €68.30 and its highest was €105.70 in the past 12 months.
What is BioNTech SE’s market cap?
BioNTech SE’s market cap is €19.95B.
When is BioNTech SE’s upcoming earnings report date?
BioNTech SE’s upcoming earnings report date is Nov 03, 2026 which is in 74 days.
How were BioNTech SE’s earnings last quarter?
BioNTech SE released its earnings results on Aug 04, 2026. The company reported -€3.24 earnings per share for the quarter, missing the consensus estimate of -€2.1 by -€1.14.
Is BioNTech SE overvalued?
According to Wall Street analysts BioNTech SE’s price is currently Undervalued.
Does BioNTech SE pay dividends?
BioNTech SE does not currently pay dividends.
What is BioNTech SE’s EPS estimate?
BioNTech SE’s EPS estimate is 0.74.
How many shares outstanding does BioNTech SE have?
BioNTech SE has 251,204,360 shares outstanding.
What happened to BioNTech SE’s price movement after its last earnings report?
BioNTech SE reported an EPS of -€3.24 in its last earnings report, missing expectations of -€2.1. Following the earnings report the stock price went down -0.735%.
Which hedge fund is a major shareholder of BioNTech SE?
Currently, no hedge funds are holding shares in DE:22UA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioNTech SE Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€109.22 (34.42% Upside)
€109.22 (34.42% Upside)
Blogger Sentiment
Bullish
DE:22UA Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 86%
Bearish news 14%
Bearish news 14%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.43%
Trailing 12-Months
Company Description
BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
22UA Company Deck
22UA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balances meaningful near‑term financial headwinds (sharp Q2 revenue decline, guidance reduction, increased SG&A and some timeline pushes) against substantial clinical and strategic progress: multiple encouraging Phase II signals (pumitamig, gotistobart), initiation of a Phase III for LCD, continued advancement of mRNA oncology programs, a strong cash position (EUR 16.6B) and active capital return. The pipeline momentum and capital strength mitigate short‑term revenue weakness, but the quarter highlights both execution progress and clear near‑term commercial challenges.View all DE:22UA earnings summaries22UA Stock 12 Month Forecast
Average Price Target
€109.22
▲(34.42% Upside)